Dr. Anthony Sabatelli, Partner and Chair of Dilworth IP’s Pharmaceutical and Biotechnology group has recently also been named Chair of CURE’s (Connecticut United for Research Excellence) Government Affairs Committee.  In that role last week, he testified before the State of Connecticut’s Finance, Revenue, and Bonding Committee advocating for the continued R&D tax credit for businesses as a “competitive necessity”, especially as it impacts the state’s growing biotechnology and pharmaceutical industry.  Governor Malloy has proposed reducing this tax credit in the state’s 2015 budget, a proposal that CURE and Sabatelli seek to reverse for fear that it “would discourage innovation, reduce jobs, hinder long-term economic growth, and have a chilling effect on investment in Connecticut. Furthermore, the proposal would damage Connecticut’s business reputation, which the State has worked so hard to improve.”

Dr. Sabatelli’s entire testimony can be found HERE.